Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna
Tillman Gerngross is taking a group of antibodies identified by his discovery group Adimab and handing them over to Arsanis, a Vienna-based biotech he co-founded to develop some of the programs he has set up at the mother ship in Lebanon, NH. And the biotech has a $9.3 million grant from the Bill & Melinda Gates Foundation to get the work through IND-enabling studies.
The target this time is RSV, or respiratory syncytial virus, which infects the respiratory system.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.